Compare

Climb Bio/$CLYM

1D1W1M3M6MYTD1Y5YMAX

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Ticker
$CLYM
Sector
Health
Primary listing
NASDAQ
Employees
29

Climb Bio Metrics

BasicAdvanced
$545M
-
-$0.82
-0.01
-

What the Analysts think about Climb Bio

Analyst ratings (Buy, Hold, Sell) for Climb Bio stock.
Analyst projections of the future price of Climb Bio stock.

Bulls say / Bears say

CLYM116 has shown sustained APRIL suppression and about a 70% reduction in disease-linked Gd-IgA1 after one dose in healthy volunteers. If Phase 2 confirms these effects in patients, its potential 12-week dosing interval could make treatment less burdensome. (Climb Bio)
Budoprutug has produced early biological activity in primary membranous nephropathy: in the 200 mg Phase 2 group, five of 13 patients reached immunologic remission by Week 12, and the treatment was generally well tolerated so far. Higher doses are being tested, with further trial data expected in 2027. (SEC)
Climb Bio reported $227.6 million in cash, equivalents and marketable securities at the end of September, which it expects to fund operations into the second half of 2028. That gives it room to advance both lead programmes and reach several planned clinical readouts before its stated runway ends. (SEC)
The budoprutug result is still an early, small-cohort signal: the remission measure was immunological, not proof of improved kidney outcomes, and only 13 patients were in the reported 200 mg group. More follow-up and data from other doses are not expected until 2027. (SEC)
CLYM116 faces established competition in IgA nephropathy: sibeprenlimab is already approved, while atacicept and povetacicept are late-stage rivals. A potentially convenient dosing schedule may not be enough if competitors build clinical and commercial leads first. (Investing.com)
Climb Bio has no approved products or product-sales revenue and continues to lose money; it reported a $41.8 million net loss and $36.9 million of operating cash outflow in the first nine months of 2026. It says the current cash balance should last into the second half of 2028, but it expects to need substantial future financing, which could dilute shareholders. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

Climb Bio Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Climb Bio Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing Climb Bio

Funds
Fund name
Fund size
$CLYM weighting
SPDR Russell 2000 US Small Cap€R2US
$4.7B0.01%
SPDR Russell 2000 US Small Cap£R2SC
$4.7B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.